Skip to content

CareSuperb COVID-19 Antigen Test Usability

CareSuperb COVID-19 Antigen Home Test Usability Study

Status
Completed
Phases
NA
Study type
Interventional
Source
ClinicalTrials.gov
Registry ID
NCT05629455
Enrollment
30
Registered
2022-11-29
Start date
2022-11-17
Completion date
2022-11-22
Last updated
2023-02-06

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

COVID-19

Brief summary

The purpose of this study is to evaluate the usability of the CareSuperb COVID-19 Antigen Home Test in Home Use.

Detailed description

COVID-19 is a contagious respiratory illness, caused by infection with the novel coronavirus Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV-2). This communicable disease is easily transmitted through aerosolized droplets containing the infectious virus. Infections with SARS-CoV-2 can have varying degrees of signs and symptoms, ranging from asymptomatic to severe. Individuals infected with SARS-CoV-2 are believed to be contagious from as early as two days prior to symptom onset to at least ten days after the onset of symptoms. The rapid detection of infections and contacts and the implementation of infection control measures are critical for mitigation of this virus. The CareSuperb COVID-19 Antigen Home Test is a lateral flow immunochromatographic assay intended for the qualitative detection of the nucleocapsid protein antigen from SARS-CoV-2 from individuals with or without symptoms or other epidemiological reasons to suspect a COVID-19 infection. This kit is intended for non-prescription home use with self-collected direct anterior nares swab samples from individuals ages 14 years and older or adult lay user-collected anterior nares swab samples from individuals aged 2 to 13 years.

Interventions

At home COVID-19 antigen test kit

Sponsors

AccessBio, Inc.
Lead SponsorOTHER

Study design

Allocation
NON_RANDOMIZED
Intervention model
PARALLEL
Primary purpose
DIAGNOSTIC
Masking
NONE

Intervention model description

This is an open label study to evaluate the usability of the CareSuperb COVID-19 Antigen Home Test using information from the Quick Reference Instructions (QRI).

Eligibility

Sex/Gender
ALL
Age
2 Years to No maximum
Healthy volunteers
Yes

Inclusion criteria

1. An Institutional Review Board (IRB) approved informed consent / assent, if applicable, is signed and dated prior to any study-related activities. 2. Male and female subjects 2 years of age and older. 3. Subject is willing to provide a self-collected nasal swab sample. (If the subject is under the age of 14, an adult lay-user will collect the sample.) 4. Subject agrees to complete all aspects of the study.

Exclusion criteria

1. Subject has a visual impairment that cannot be restored with glasses or contact lenses. 2. Subject has prior medical or laboratory training. 3. Subject uses home diagnostics, e.g., glucose meters, HIV tests. 4. Subject has prior knowledge of their current COVID-19 infection status.

Design outcomes

Primary

MeasureTime frameDescription
Usability of Quick Reference InstructionOne monthPrimary Endpoints: 1. Assess the usability of the Quick Reference Instructions (QRI) based upon observer evaluation.
Usability of Test KitOne monthPrimary Endpoints: 2. Assess the usability of the kit for home use based upon subject evaluation.

Countries

United States

Outcome results

None listed

Source: ClinicalTrials.gov · Data processed: Feb 4, 2026